A thymus-made immune-signaling peptide that balances rather than boosts immunity. Long used as a prescription drug abroad for chronic viral infections and some cancers; its best-supported effect is restoring weakened immunity, including better vaccine response in older adults. The healthy-aging promise remains unproven, and product quality and legal status are uncertain. (Full Review)

Protocol

Dose & Route

1.6 mg subcutaneous, twice weekly

Spaced 3–4 days apart (e.g., Monday and Thursday)

Course Length

6–12 months

Time-limited courses; longevity use is intermittent cycles, not continuous

Form

Reconstituted injection

Lyophilized powder reconstituted with sterile water; not orally bioavailable

Time to effect

Immune Markers

Within weeks

Immune-marker changes such as T-cell counts

Viral Control

Over months

Clinically meaningful effects build during and after a full course

Vaccine Response

Around vaccination

Improved antibody response when timed around immunization

Benefits

High: Immune restoration in immunosuppressed states

Medium: Enhanced vaccine response in older adults; improved outcomes in chronic hepatitis B

Low: Reduced mortality in sepsis; adjunct activity in cancer immunotherapy

Speculative: Countering immunosenescence for healthy longevity; reduced frequency and severity of recurrent infections

Contraindications

Active autoimmune disease (e.g., lupus, rheumatoid arthritis, autoimmune thyroiditis, flaring or systemically active)

Solid-organ transplant recipients and others on required immunosuppression (particularly first 6–12 months post-transplant or during active rejection)

Pregnancy or breastfeeding

Known hypersensitivity to the peptide or formulation excipients

Key Interactions

Interferons (e.g., interferon alfa, pegylated interferon)

Immunosuppressant drugs (e.g., corticosteroids, calcineurin inhibitors such as tacrolimus and cyclosporine, transplant anti-rejection drugs)

Immune-checkpoint inhibitors (e.g., pembrolizumab, nivolumab)

Immune-stimulating supplements (e.g., high-dose echinacea, beta-glucans)

Risk & Side Effects

High: Injection-site reactions

Medium: Purity, contamination, and immunogenicity risk of unregulated sourcing

Low: Systemic flu-like and constitutional effects; theoretical overstimulation in autoimmune or transplant settings

Speculative: Possible harm in younger or non-immunosuppressed individuals; unknown long-term and oncological effects

Monitoring

Marker	Target	Why
CD4/CD8 T-cell ratio	~1.5–2.5	Core readout of the T-cell balance the peptide targets
CD4+ T-cell count	~600–1,500 cells/µL	Tracks helper T-cell reconstitution, the peptide's most consistent effect
Total lymphocyte count	~1,500–3,000 cells/µL	Broad, low-cost marker of immune cell availability
hs-CRP	<1.0 mg/L	Gauges the chronic low-grade inflammation of immune aging that the peptide may help temper
Neutrophil count (if combined with interferon)	~2,500–6,000 cells/µL	Detects neutropenia, the main blood-count risk of interferon co-therapy
Fasting glucose / HbA1c	Glucose ~70–90 mg/dL; HbA1c <5.4%	Diabetes status flags a subgroup with a possible differential response

Cadence: Baseline, then ~4–8 weeks into a course to gauge early response, then every 3–6 months during continued or repeated use

Qualitative Assessment

Frequency, duration, and severity of infections (e.g., colds, respiratory illness) over a season
Recovery time and resilience after illness or physical stress
Subjective energy and sense of vitality
Response to vaccination, where testable

Thymosin Alpha-1 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment